Source:http://linkedlifedata.com/resource/pubmed/id/20836579
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
14
|
pubmed:dateCreated |
2010-9-14
|
pubmed:abstractText |
Lopinavir/ritonavir (Kaletra®) is an orally administered coformulated ritonavir-boosted protease inhibitor (PI) comprising lopinavir and low-dose ritonavir. It is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults, adolescents and children. Lopinavir/ritonavir is available as a tablet, soft-gel capsule and an oral solution for patients with difficulty swallowing. In well designed, randomized clinical trials, lopinavir/ritonavir, in combination with other antiretroviral therapies (ART), provided durable virological suppression and improved immunological outcomes in both ART-naive and -experienced adult patients with virological failure. Furthermore, lopinavir/ritonavir demonstrated a high barrier to the development of resistance in ART-naive patients. More limited data indicate that it is effective in reducing plasma HIV-1 RNA levels in paediatric patients. Lopinavir/ritonavir has served as a well established benchmark comparator for the noninferiority of other ritonavir-boosted PI regimens. Although generally well tolerated, lopinavir/ritonavir is associated with generally manageable adverse gastrointestinal side effects and hypertriglyceridaemia and hypercholesterolaemia, which may require coadministration of lipid-lowering agents to reduce the risk of coronary heart disease. Lopinavir/ritonavir, in combination with other ART agents, is a well established and cost-effective treatment for both ART-naive and -experienced patients with HIV-1 infection and, with successful management of adverse events, continues to have a role as an effective component of ART regimens for the control of HIV-1 infection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Lopinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones,
http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0012-6667
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
70
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1885-915
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:20836579-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:20836579-Drug Administration Schedule,
pubmed-meshheading:20836579-Drug Combinations,
pubmed-meshheading:20836579-HIV Infections,
pubmed-meshheading:20836579-HIV Protease Inhibitors,
pubmed-meshheading:20836579-HIV-1,
pubmed-meshheading:20836579-Humans,
pubmed-meshheading:20836579-Lopinavir,
pubmed-meshheading:20836579-Pyrimidinones,
pubmed-meshheading:20836579-Ritonavir
|
pubmed:year |
2010
|
pubmed:articleTitle |
Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.
|
pubmed:affiliation |
Adis, Auckland, New Zealand. demail@adis.co.nz
|
pubmed:publicationType |
Journal Article,
Review
|